<DOC>
	<DOCNO>NCT02924883</DOCNO>
	<brief_summary>This phase II , double-blind , randomize , placebo-controlled multicenter study investigate efficacy safety trastuzumab emtansine combination atezolizumab atezolizumab-placebo participant HER2-positive locally advanced metastatic breast cancer receive prior trastuzumab taxane base therapy , either alone combination , and/or progress within 6 month complete adjuvant therapy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Trastuzumab Emtansine Combination With Atezolizumab Atezolizumab-Placebo Participants With Human Epidermal Growth Factor-2 ( HER2 ) Positive Locally Advanced Metastatic Breast Cancer Who Have Received Prior Trastuzumab Taxane Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Archival tumor sample must obtain primary and/or metastatic site Able submit tumor tissue evaluable program death ligand 1 ( PDL1 ) expression HER2 positive breast cancer ( BC ) define immunohistochemistry ( IHC ) score 3 gene amplify insitu hybridization ( ISH ) define ratio great equal ( &gt; /= ) 2.0 number HER2 gene copy number chromosome 17 copy Histologically cytologically confirm invasive BC : incurable , unresectable , locally advanced BC previously treat multimodality therapy metastatic breast cancer ( MBC ) Prior treatment BC : adjuvant ; unresectable locally advance ; metastatic setting ; must include , taxane trastuzumab ( alone combination another agent ) Progression must occur recent treatment locally advance BC/MBC within 6 month complete adjuvant therapy Participants must measurable disease evaluable per RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Negative serum pregnancy test premenopausal woman woman le 12 month onset menopause Use highly effective method contraception define protocol Prior treatment trastuzumab emtansine , cluster differentiation 137 ( CD137 ) agonists , antiPD1 , antiPDL1 therapeutic antibody pathwaytargeting agent Receipt anticancer drug/biologic investigational treatment within 28 day prior randomization except hormone therapy , give 7 day prior randomization ; recovery treatment related toxicity consistent eligibility criterion Radiation therapy within 2 week prior Cycle 1 , Day 1 History exposure cumulative dos anthracyclines History malignancy within previous 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , participant undergo potentially curative therapy evidence disease deem treat physician low risk recurrence Cardiopulmonary dysfunction , symptomatic pleural effusion , pericardial effusion , ascites Current severe , uncontrolled systemic disease Major surgical procedure significant traumatic injury within 28 day prior randomization anticipation need major surgery course study treatment Clinically significant history liver disease , include cirrhosis , current alcohol abuse , autoimmune hepatic disorder , sclerosis cholangitis active infection human immunodeficiency virus , hepatitis B virus , hepatitis C virus Need current chronic corticosteroid therapy ( &gt; /=10 mg prednisone per day equivalent dose antiinflammatory corticosteroid ) Spinal cord compression definitively treat surgery and/or radiation , previously diagnose treat spinal cord compression without evidence disease clinically stable great ( &gt; ) 2 week prior randomization Participants know central nervous system disease History autoimmume disease Prior allogeneic stem cell solid organ transplantation Active tuberculosis Receipt live , attenuate vaccine within 4 week prior randomization anticipation live , attenuated vaccine require study Treatment systemic immunostimulatory agent within 4 week five halflives drug ( whichever short ) prior randomization Treatment systemic corticosteroid systemic immunosuppressive medication within 2 week prior randomization , anticipated requirement systemic immunosuppressive medication trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>